The COVID-19 pandemic remains an international public health emergency, and the emergence of new SARS-CoV-2 variants highlights concerns regarding COVID-19 breakthrough infections. Understanding emerging SARS-CoV-2 variants is especially important as the medical and public health community seeks to contain COVID-19. In this interview, Dr Hiam Chemaitelly (Weill Cornell Medicine-Qatar, Ar-Rayyan, Qatar) talked to us about the COVID-19 vaccination program in Qatar, the efficacy of the Moderna vaccine and much more.
‘COVID-19 vaccine effectiveness against SARS-CoV-2 variants’ was presented at the annual International Conference on Emerging Infectious Diseases (ICEID), August 7–10, 2022.
- Could you tell us a little about the vaccination programme against SARS-CoV-2 in Qatar? (00:16)
- What is known about the efficacy of the mRNA-1273 (Moderna) vaccine against ‘wild type’ variants of SARS-CoV-2? (0:43)
- What were the aims and design of your study? (02:09)
- What were the findings in terms of efficacy against different variants? (03:20)
- What challenges do you anticipate in the vaccination programme in the coming winter, and how may they be overcome? (06:29)
Disclosures: Hiam Chemaitelly has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Marianna Mignani.Â
Filmed as a highlight of ICEID 2022
